Leah Kuntz

Today is International Overdose Awareness Day!

A recent survey found mental health and finances were some of the top stressors for college students.

The 988 Implementation Act was introduced on July 25. What impact will it have on care?

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.

Learn more about a comprehensive system of care for those who are in crisis and need immediate access to care, aided by the new 988 Suicide & Crisis Lifeline.

Fasedienol meets trial endpoints by reducing anxiety during public speaking simulations in patients with social anxiety disorder.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.

A new cognitive biotype for depression may impact symptoms and treatment outcomes.

Did you miss our APA Annual Meeting coverage?

What is it like to be a 988 counselor?

A year ago, the National Suicide Prevention Lifeline switched to its new 3-digit number, 988. What's happened since then?

Nearly 1 in 2 women compare themselves to Barbie.

New research finds depressive and anxiety symptoms impact effectiveness of cognitive behavioral therapy for insomnia.

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

Neuroimaging could help predict clinical response to treatment in bipolar depression.

New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.

Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.

In honor of Memorial Day...

Presenters at the 2023 APA Annual Meeting compared definitions of treatment-resistant depression.

Psychiatric Times’ very own H. Steven Moffic, MD, spoke about resilience and religion at the 2023 APA Annual Meeting.

Learn more about women’s issues, suicide, and PTSD in the military.

Deutetrabenazine extended-release tablets are now available.

Here are some things to check out in the city while you're in town...

Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

Ulotaront, a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity, is under investigation for the treatment of generalized anxiety disorder.

New results for a study evaluating lumateperone.

Recent research evaluated evenamide as an add-on to an antipsychotic for patients with treatment-resistant schizophrenia.

We connected with a group working on the frontlines of Southern Turkey and Northern Syria to assist the survivors of the devastating earthquake.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.